...
首页> 外文期刊>BMC research notes >Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples
【24h】

Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples

机译:打开档案进行最新的肿瘤遗传研究:使用脱钙的,福尔马林固定的,石蜡包埋的组织来源的DNA样品处理阵列CGH

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Molecular genetic studies on rare tumour entities, such as bone tumours, often require the use of decalcified, formalin-fixed, paraffin-embedded tissue (dFFPE) samples. Regardless of which decalcification procedure is used, this introduces a vast breakdown of DNA that precludes the possibility of further molecular genetic testing. We set out to establish a robust protocol that would overcome these intrinsic hurdles for bone tumour research. Findings The goal of our study was to establish a protocol, using a modified DNA isolation procedure and quality controls, to select decalcified samples suitable for array-CGH testing. Archival paraffin blocks were obtained from 9 different pathology departments throughout Europe, using different fixation, embedding and decalcification procedures, in order to preclude a bias for certain lab protocols. Isolated DNA samples were subjected to direct chemical labelling and enzymatic labelling systems and were hybridised on a high resolution oligonucleotide chip containing 44,000 reporter elements. Genomic alterations (gains and losses) were readily detected in most of the samples analysed. For example, both homozygous deletions of 0.6 Mb and high level of amplifications of 0.7 Mb were identified. Conclusions We established a robust protocol for molecular genetic testing of dFFPE derived DNA, irrespective of fixation, decalcification or sample type used. This approach may greatly facilitate further genetic testing on rare tumour entities where archival decalcified, formalin fixed samples are the only source.
机译:背景技术对稀有肿瘤实体(例如骨肿瘤)的分子遗传学研究通常需要使用脱钙的,福尔马林固定的,石蜡包埋的组织(dFFPE)样品。无论使用哪种脱钙程序,都会导致DNA大量分解,从而无法进行进一步的分子遗传学检测。我们着手建立一个可靠的协议,以克服这些固有的障碍来进行骨肿瘤研究。研究结果我们的研究目标是建立一个使用改良的DNA分离程序和质量控制程序的方案,以选择适合于阵列CGH测试的脱钙样品。从欧洲的9个不同病理科获得档案石蜡块,使用不同的固定,包埋和脱钙程序,以防止对某些实验室规程产生偏见。将分离的DNA样品进行直接化学标记和酶标记系统,并在包含44,000个报告元件的高分辨率寡核苷酸芯片上杂交。在分析的大多数样品中都容易检测到基因组变化(收益和损失)。例如,鉴定出0.6 Mb的纯合缺失和0.7 Mb的高水平扩增。结论我们建立了一个可靠的协议,用于dFFPE衍生DNA的分子遗传学测试,无论使用的是固定,脱钙还是样品类型。这种方法可以极大地促进对罕见的肿瘤实体进行进一步的基因测试,在这些实体中,存档脱钙的,福尔马林固定的样品是唯一的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号